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Potassium and Cardiac Surgery
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Abstract
Potassium homeostasis affects cardiac rhythm and contractility, along with  
vascular reactivity and vascular smooth muscle proliferation. This chapter will 
focus on potassium dynamics during and after cardiac surgery involving cardiople-
gic arrest and cardiopulmonary bypass (CPB). Hyperkalemic, hypothermic solu-
tions are frequently used to induce cardioplegic arrest and protect the heart during 
cardiac surgery involving CPB. Common consequences of hyperkalemic cardiople-
gic arrest and reperfusion include microvascular dysfunction involving several 
organ systems and myocardial dysfunction. Immediately after CPB, blood potas-
sium levels often drop precipitously due to a variety of factors, including CPB - 
induced electrolyte depletion and frequent, long-term administration of insulin 
during and after surgery. Meanwhile, some patients with pre-existing kidney dys-
function may experience postoperative hyperkalemia following cardioplegia. Any 
degree of postoperative hyper/hypokalemia significantly elevates the risk of cardiac 
arrythmias and subsequent myocardial failure. Therefore, proper management of 
blood potassium levels during and after cardioplegia/CPB is crucial for optimizing 
patient outcomes following cardiac surgery.
Keywords: potassium, hypokalemia, hyperkalemia, low potassium, high potassium, 
hyperkalemic cardioplegia, cardiopulmonary bypass, cardiac surgery, open heart 
surgery, postoperative arrhythmias, perioperative arrhythmias
1. Introduction
Intracellular and blood potassium levels have crucial effects on cardiovascular 
system homeostasis. At the most fundamental level, the potassium concentration 
gradient across cardiac muscle cell (cardiomyocyte) cell membranes is a chief 
determinant of cardiomyocyte resting membrane potentials. Indeed, disruptions 
to this concentration gradient (e.g. via increasing or decreasing extracellular blood 
potassium levels) can lead to altered cardiomyocyte contractility and excitability. 
Potassium is also vasoactive, with different effects at different extracellular concen-
trations. At low (5-8 mM) to moderate (8-16 mM) extracellular levels, potassium 
relaxes the smooth muscle in blood vessel walls by promoting hyperpolarization 
of vascular smooth muscle. However, at higher levels (16-25 mM and above) (e.g. 
cardioplegic concentrations), potassium promotes vasoconstriction by facilitating 
depolarization. Moreover, potassium is released by vascular endothelial cells in 
response to various chemical mediators and shear stress, thereby contributing to the 
action of endothelium-derived hyperpolarizing factor [1]. For all of these reasons 
and more, keeping track of daily potassium intake is often recommended as a 
lifestyle modification for chronic cardiovascular diseases such as hypertension.
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Harnessing the pivotal role of potassium in cardiovascular physiology has 
proved quite useful for cardiovascular surgery, namely in the form of hyperkalemic 
(high potassium) cardioplegia. Indeed, throughout the past several decades, a large 
body of research has testified to the ability of externally administered hyperkalemic 
solutions to arrest cardiac contractility [2]. This, in conjunction with the develop-
ment of cardiopulmonary bypass (CPB, also known as the “heart-lung machine”), 
revolutionized cardiac surgery [3]. These days, many highly invasive procedures 
like coronary artery bypass grafting are routine with minimal risk of postoperative 
mortality.
However, hyperkalemic cardioplegia is not without its consequences. 
Hyperkalemic cardioplegia and reperfusion following CPB have been associated 
with perioperative and postoperative tissue damage and microvascular dysfunction 
across several different vascular beds. Moreover, hyperkalemic cardioplegia is also 
associated with postoperative myocardial dysfunction and reduced cardiac output. 
Furthermore, blood potassium abnormalities after hyperkalemic cardioplegia-
reperfusion, chiefly hypokalemia (but also hyperkalemia, to a lesser degree) are 
common postoperative challenges in the cardiac ICU. Both abnormalities signifi-
cantly elevate the risk of arrythmias and, if not managed properly, cardiac arrest 
and sudden death.
This chapter will discuss the basics of potassium cardioplegia with an emphasis 
on clinical relevance, beginning with a brief history. Subsequent sections will elabo-
rate on the basic physiology, before considering several perioperative and postop-
erative adverse effects of hyperkalemic cardioplegia. When possible, information 
about treatment and clinical management is included. The chapter will conclude 
with a brief mention of up-and-coming alternatives to hyperkalemic cardioplegia.
2. Potassium and cardiac surgery
2.1 Brief history of potassium cardioplegia
As early as the late 1800s, physiologists were starting to become aware of the 
ability of potassium compounds to arrest cardiac contractility, beginning with 
individuals like Sidney Ringer who observed that potassium chloride froze the heart 
in diastole and calcium stimulated the heart during systole [2]. Moving into the 
start of the 20th century, further investigations revealed associations between high 
serum potassium and cardiac arrest following ventricular fibrillation; studies also 
revealed associations between cardioplegia and restoration of sinus rhythm follow-
ing coronary artery administration of potassium chloride solution and subsequent 
washout [2]. However, in most of these cardioplegic experiments (often conducted 
in dogs), refractory ventricular fibrillation and post-procedure reperfusion damage 
to the myocardium limited discussion of the clinical usefulness of these findings.
During the 1950s, British physician Dennis Melrose hypothesized that the 
problem with potassium chloride cardioplegia was chloride; therefore, he created 
a cardioplegic solution using potassium citrate, and tested it on a canine model 
of cardiopulmonary bypass [4]. Injection of the “Melrose solution”, of potassium 
citrate plus warm oxygenated whole blood in a 9:1 blood:potassium ratio, into 
the aortic roots of hypothermic dogs, produced near-immediate cardiac arrest. 
Reperfusion and washout of cardioplegic solution resulted in restoration of heart 
function to pre-procedure levels [2]. Within a few years, the Melrose group success-
fully induced potassium citrate cardioplegia in humans.
Unfortunately, future studies would reveal that in many cases, the Melrose 
potassium citrate solution still produced post-cardioplegia ventricular fibrillation 
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and myocardial dysfunction [5]. This led to a general pause in clinical application of 
potassium cardioplegia between the 1960s and early 1980s, in favor of other options 
mostly involving induction of hypothermic cardiac arrest, which turned out to be 
no better with respect to postoperative damage than the Melrose solution.
Eventually, research into techniques for potassium cardioplegia would pick up 
again, and the result would be development of novel solutions for cardioplegia 
and intraoperative organ preservation. Numerous studies in animal models have 
validated the principles of diastolic cardiac arrest due to depolarizing potassium 
cardioplegia [2, 3, 6–10]. In addition, invention and refinement of heart-lung 
machines to accompany cardioplegia in the operative room (CPB) opened many 
new possibilities for cardiac surgery. Today, potassium cardioplegia is an integral 
tool for cardiac surgeons performing a variety of highly invasive procedures such as 
coronary artery bypass grafting and aortic valve replacements.
2.2 Types and techniques of potassium cardioplegia
Despite variability in composition, delivery, and temperature, most cardioplegic 
solutions in use today involve some level of potassium chloride as the main inducer 
of cardiac arrest, along with ions such as magnesium, low-dose calcium and bicar-
bonate, the latter of which is particularly important for controlling solution pH [6]. 
The “original” hyperkalemic cardioplegic solution was the Melrose formula of the 
1950s that was discussed earlier, consisting of potassium citrate and warm blood 
in a 9:1 blood:potassium ratio. However, due to the high incidence of postoperative 
complications including ventricular fibrillation, this solution is no longer in major 
clinical use.
2.2.1 Crystalloid vs. blood
In general, cardioplegic solutions fall under two broad umbrellas: crystalloid vs. 
blood, and warm vs. cold (Table 1). Two crystalloid cardioplegic solutions worth 
noting are the Custodiol (also known as Bretschneider) and St. Thomas solutions 
[7]. The St. Thomas solution, introduced first by Hearse and colleagues in 1975, is 
an example of a short acting cardioplegic solution involving potassium chloride 
concentrations between 10 and 30 mM [8]. In general, the St. Thomas solution 
requires repeat dosing, roughly every 20 minutes, to sustain cardioplegia for long 
durations [7, 9]. Furthermore, myocardial acidosis has been noted between doses of 
St. Thomas solution [10].
In contrast, the Custodiol solution is a form of long acting, single dose cardiople-
gia consisting primarily of potassium chloride, sodium chloride, and magnesium 
sulfate as the chief electrolytes [11]. Additional components of the Custodiol solu-
tion include tryptophan (membrane stabilization) and histidine buffer (to maintain 
pH and buffer against byproducts of anaerobic glycolysis that build up during 
cardioplegia). Curiously, the relatively low levels of potassium (9 mM) and sodium 
(15 mM) in Custodiol appear to induce cardioplegia through a form of hyperpolar-
ized arrest as opposed to depolarized arrest, unlike most other potassium cardiople-
gic solutions that have potassium concentrations in the range of 16-36 mM and 
sodium concentrations in the range of 10-110 mM (see Table 1 for detailed solution 
ion concentrations).
The general rationale for blood-based cardioplegia has centered on the theory 
that cardioplegic solutions containing blood are more “physiologic” than crystal-
loid solutions. For example, blood can support aerobic respiration and may be 
able to preserve normal myocardial metabolism during surgery. Therefore, blood 
















Custodiol Cardioplegia Del Nido 
Cardioplegia
Buckberg Cardioplegia Warm Calafiore Cardioplegia (one variant)
K+ 16 mM 9 mM 26 mM Cold induction: 36 mM Maintenance: 36 mM
Reperfusion: 15 mM
18–20 mM for inducing arrest, repeat delivery 
every 20 min with decreasing K concentrations
Ca 1.2 mM 0.015 mM 1.3 mM















13 mL of 1% 
lidocaine
3.2 g/L of 20% 
mannitol
Cold Induction: 392 mL 5% dextrose, 
50 mL 0.3 M tromethamine, 30 mL 
citrate–phosphate-2-dextrose
Maintenance: 798 mL 5% dextrose, 
123 mL 0.3 M tromethamine, 61 mL 
citrate–phosphate-2-dextrose
Reperfusion: 26 mL 50% dextrose; 









Crystalloid Crystalloid 4:1 crystalloid: 
blood ratio
4:1 crystalloid: blood ratio Normothermic blood
Table 1. 
Composition of common potassium-based cardioplegic solutions.
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CPB [11]. However, insufficient evidence exists currently to verify that hypothesis, 
and so any purported advantages of blood over crystalloid cardioplegia are for the 
time being mainly speculative.
Three hyperkalemic cardioplegic solutions in clinical use that contain blood 
are the Del Nido, Buckberg, and Calafiore solutions. The Del Nido solution uses 
a crystalloid:blood ratio of 4:1, and like the Custodiol solution is a long-acting 
cardioplegic solution, with one dose of 20 ml/kg providing myocardial protec-
tion for up to 60–90 minutes [7, 12]. Chief ionic ingredients include potassium 
chloride for rapid depolarized arrest, sodium bicarbonate to scavenge protons and 
buffer intracellular pH, and magnesium to block calcium channels and prevent 
intracellular calcium accumulation during cardioplegic arrest, thereby promoting 
postoperative myocardial recovery [12, 13]. Lidocaine in the Del Nido solution acts 
as a sodium channel blocker to mitigate against the sodium “window current” and 
reduce intracellular sodium accumulation [14].
Buckberg’s cardioplegia is a dextrose and saline-based solution that, similar to 
the Del Nido solution, consists of a crystalloid:blood ratio of 4:1 [15]. Other com-
ponents include potassium chloride as the primary depolarizing agent, a trometh-
amine buffer, and citrate phosphate double dextrose to serve as a calcium chelator. 
However, unlike the Del Nido solution, Buckberg cardioplegia must be given as 
three separate formulations, some of which must be administered in multiple 
doses [15]. First, an induction solution stops the heart, and additional infusions of 
induction solution must be given every 15 to 20 minutes throughout the procedure. 
Second, a maintenance solution must be administered to sustain cardiac arrest and 
provide oxygen and nutrients to the cardiomyocytes. Finally, a reperfusion solu-
tion containing glutamate and aspartate is administered prior to removal of the 
aortic cross clamp to provide the heart with nutrients prior to restarting myocardial 
contractions.
Calafiore cardioplegia differs from Buckberg and Del Nido in that blood forms 
the sole foundation of Calafiore cardioplegic solution [16]. Indeed, the original 
rational proposed by Calafiore et al. was that blood alone, without any crystalloid 
component, contained everything necessary to prevent ischemia–reperfusion dam-
age. Therefore, simply administering a cardioplegic solution consisting of blood 
plus extra potassium would be enough to safely stop and later, restart the heart [16]. 
Moreover, unlike most other forms of cardioplegia in use, the original Calafiore 
solution was normothermic throughout administration; however, some subsequent 
variations of Calafiore cardioplegia have used cold blood [16, 17].
2.2.2 Warm vs. cold
Most current methods for administering cardioplegic solutions involve cold 
cardioplegia, most often cold crystalloid solutions delivered after reducing core 
body temperature to hypothermic levels [18]. For example, the induction and 
maintenance solutions for Buckberg cardioplegia are delivered at 4 degrees Celsius 
after cooling core temperature to below 30 degrees Celsius, with reperfusion 
solution delivered at 37 degrees Celsius [15]. Similarly, del Nido and Custodiol 
cardioplegia are often given at 4 degrees Celsius after induction of systemic 
hypothermia [15, 19].
This practice stems from experimental evidence suggesting that mild hypother-
mia can protect the myocardium from ischemic damage during cardioplegia [20]. 
Hypothermia reduces the basal metabolic rate of the heart, which in turn reduces 
oxygen consumption—an effect augmented by potassium-induced arrest during 
hyperkalemic cardioplegia [21]. A variety of potential mechanisms may be at play. 
In animal models of cardiac arrest, mild hypothermia (32–35 degrees Celsius) 
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has been shown to reduce post-arrest infarct size, possibly through various signal 
transduction pathways, such as Akt and mTOR signaling, both of which are altered 
during the course of hypothermia [20]. Another potential cardioprotective mecha-
nism of hypothermia may be reduced phosphorylation of various mitogen activated 
protein kinases (MAPK) like ERK1/2 that normally activate pro-inflammatory 
mediators like COX-2 (arachidonic acid metabolism) [18]. In general, many details 
concerning mechanisms of hypothermic myocardial protection during cardioplegia 
remain to be elucidated.
However, cold hyperkalemic cardioplegia may also inhibit myocardial enzymes 
that are important for the metabolic and functional recovery of the heart after 
surgery [22, 23]. Moreover, sustained systemic hypothermia (especially at tempera-
tures below 20 degrees Celsius) during cardiac surgery has also been associated 
with ventricular fibrillation after rewarming [21]. Given these negative conse-
quences, an increasing amount of attention has been given to the possibility of 
warm hyperkalemic cardioplegia, primarily warm blood hyperkalemic cardioplegia. 
Unlike cold hyperkalemic cardioplegic solutions, warm cardioplegic solution is 
typically administered at between 30 and 35 degrees Celsius under normother-
mic, as opposed to hypothermic, CPB [24]. Potential advantages of warm blood 
hyperkalemic cardioplegia over cold crystalloid may include improved myocardial 
restoration, reduced intracellular swelling, improved membrane stabilization, and 
reduced hypoxic red blood cell deformation [25].
Of course, warm hyperkalemic cardioplegia is not without its own conse-
quences. Some studies have reported increased likelihoods of perioperative strokes 
and encephalopathy [26]. Moreover, warm hyperkalemic cardioplegia may con-
tribute to vasodilation during cardiopulmonary bypass, requiring increased use 
of alpha agonists during operation to maintain stable arterial perfusion pressures 
[25]. There are also several variations of warm cardioplegia; one common technical 
variant is “hot shot” cardioplegia, which involves warm induction and subsequent 
cold cardioplegia, followed by a warm reperfusion [27].
Comparing the effectiveness of warm vs. cold hyperkalemic cardioplegia 
remains an inconclusive subject of intense debate. A meta-analysis by Fan et al., 
reported no differences between length of stay, stroke incidence, and atrial fibrilla-
tion between patients undergoing warm vs. cold cardioplegia [28]. However, warm 
cardioplegia correlated with better postoperative cardiac indices and lower peak 
creatine kinase MB concentrations than cold cardioplegia [28]. The latter findings, 
along with reduced postoperative cardiac troponin levels, have been replicated 
in other studies [29, 30]. Meanwhile, other studies comparing warm blood and 
cold crystalloid hyperkalemic cardioplegia do not show significant differences 
with respect to perioperative myocardial infarction and low cardiac output syn-
drome [31].
2.2.3 Anterograde vs. retrograde
In general, administration of hyperkalemic cardioplegic solution can be done in 
either retrograde or anterograde fashion. Prior to both, IV heparin is administered, 
and the patient’s core body temperature is lowered to hypothermic levels, after 
which the aortic cross-clamp is placed and cardiopulmonary bypass is initiated 
[7]. Anterograde cardioplegia refers to delivering cardioplegic solution through a 
cannula inserted just proximal to the aortic cross-clamp. From there, the solution 
can flow into the left and right coronary arteries that supply the myocardium [32]. 
With anterograde cardioplegia, arrest usually occurs within 30 to 60 seconds. 
Retrograde cardioplegia may be considered in patients with complications such as 
severe coronary artery damage (e.g. severe stenosis) or aortic valve damage. Unlike 
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anterograde administration, in retrograde administration the cardioplegia catheter 
is inserted into the coronary sinus from the right atrium, and solution is injected at 
a lower pressure (given the lower tolerance of the coronary sinus walls to turbulent 
flow) to avoid coronary sinus perforation [32].
2.3 Physiology of potassium cardioplegia during cardiac surgery
2.3.1 Physiology of cardiac muscle contraction
Under physiological circumstances, the cardiomyocyte resting membrane 
potential is largely determined by two key factors: action of the sodium-potassium 
ATPase, and the high resting permeability of cardiomyocyte cell membranes to 
potassium [33]. First, the sodium-potassium ATPase hydrolyzes ATP to continu-
ously pump potassium into the cell and sodium out of the cell, with a relative ratio 
of 3Na out/2 K in per molecule of ATP. Because it is the primary ion pump active 
while the cell is at rest, the sodium-potassium ATPase plays a critical role in gen-
erating the characteristic sodium and potassium electrochemical gradients across 
the cardiomyocyte cell membrane (high potassium and low sodium inside the cell 
relative to out). Second, at rest the cardiomyocyte cell membrane is most permeable 
to potassium while being relatively impermeable to other ions. This results in a rest-
ing membrane potential for cardiomyocytes that is close to the Nernst equilibrium 
potential for potassium, roughly −85 to -90 mV.
During cardiac muscle contraction, sinoatrial node stimulation induces a 
transient increase in the resting membrane potential of cardiomyocytes, which in 
turn opens voltage-gated sodium channels once the membrane potential surmounts 
-65 mV. Due to the high inward ion driving force on sodium (based on the consider-
able difference between the Nernst potential for sodium and the resting membrane 
potential), sodium ions flow through the sodium channels into the cardiomyocyte 
and further depolarize the cell until it reaches about 20 mV. At this point, sodium 
channels inactivate and L-type voltage gated calcium channels take over the main-
tenance of the action potential, allowing influx of calcium ions and producing the 
classic plateau depolarization of cardiac ventricular action potentials. Eventually, 
as calcium channels close and membrane potential begins to dip, delayed rectifier 
potassium channels open and restore membrane potential to the resting state. By 
this point, enough calcium has entered the cardiomyocyte to promote calcium-
induced calcium release from intracellular calcium stores in the cardiomyocyte 
sarcoplasmic reticula, allowing muscle contraction to occur.
2.3.2 Physiology of potassium cardioplegia
Extracellular hyperkalemia is the core principle underpinning most warm blood 
and cold crystalloid cardioplegic solutions. Essentially, administration of hyperka-
lemic solution takes advantage of the pivotal role of the potassium electrochemical 
gradient in determining cardiomyocyte resting membrane potential in order to 
elevate the resting membrane potential to a less negative value than typical baseline 
level. For example, physiologic extracellular potassium levels are often in the range 
of 3.5–5 mM, producing a resting membrane potential around -85 mV. During 
cardiac surgery involving cardioplegia, hyperkalemic solutions often raise extracel-
lular potassium to the range of 10-40 mM (often midway in this range, around the 
25 mM level), elevating cardiomyocyte resting membrane potentials to anywhere 
between −65 to -40 mV [34]. Arresting cardiomyocytes at this new range of 
elevated membrane potentials promotes fast sodium channel inactivation, thereby 
blocking myocardial action potential conduction. It also blocks repolarization, 
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which is why hyperkalemic cardioplegia induces what is called “depolarized arrest.” 
Finally, it is important to note that cardioplegic arrest also significantly reduces car-
diomyocyte oxygen consumption in a manner reminiscent of how severe ischemia 
depletes cellular ATP reserves [33].
2.4 Side effects of high potassium cardioplegia
2.4.1 Myocardial calcium loading
Despite its clinical usefulness in reversibly arresting the heart during cardiac 
surgery, sustained depolarized hyperkalemic cardioplegia is not without some 
negative perioperative consequences. First, while most voltage-gated “fast” sodium 
channels are inactivated at membrane potentials above -50 mV (a frequent target 
cardiomyocyte membrane potential for potassium cardioplegia), resulting in gener-
ally poor membrane sodium conductance, not all sodium channels are inactivated. 
Moreover, during hyperkalemic cardioplegia the ion driving force on sodium is 
still quite high, even at the new depolarized cell membrane potentials. Ultimately, 
this situation produces a small but significant sodium influx into cardiomyocytes 
through the small fraction of sodium channels that remain open during potassium 
cardioplegia, a phenomenon known as the sodium “window current” [35].
Similarly, ATP depletion and reduced myocardial oxygen consumption during 
hyperkalemic cardioplegia leads to myocardial ischemia. Ischemia forces myocar-
dial cells to resort to anaerobic glycolysis for energy production, which generates 
lactate as a byproduct. Increasing lactate levels in cardiomyocytes produces a 
metabolic acidosis and promotes increased activity of the H+/Na antiporter to move 
protons out of the cells at the expense of bringing in more sodium [36]. Finally, 
the combination of high extracellular potassium, intracellular acidosis, and hypo-
thermia due to cold cardioplegic solution inhibits action of the sodium-potassium 
ATPase, which further facilitates the buildup of intracellular sodium [34].
Note that -50 mV is also in the vicinity of the reversal potential of the sodium/
calcium exchanger [37, 38]. Under normal circumstances, the sodium/calcium 
exchanger moves 3 Na in for every 1 Ca moved out of the cell. However, due to the 
sodium window current and depolarized arrest in hyperkalemic cardioplegia, the 
sodium/calcium exchanger eventually begins operating in reverse, moving 3 Na out 
for every 1 Ca in, producing a so-called calcium “window current.” Moreover, if the 
hyperkalemic cardioplegic solution holds cardiomyocyte membrane potentials above 
-50 mV, e.g. at around -40 mV, then voltage-gated slow calcium channels will begin 
to activate, causing further calcium influx [39]. All of these reasons help explain why 
many hyperkalemic cardioplegic solutions in clinical practice are also hypocalcemic 
relative to physiological extracellular calcium levels (or contain calcium channel 
blockers), to attempt to mitigate the severity of myocardial calcium loading [34].
Cytosolic calcium loading during hyperkalemic cardioplegia contributes to 
cardiomyocyte damage through several mechanisms [40]. Enhanced activation 
of calcium dependent proteases and lipases (e.g. phospholipases) contributes 
to plasma membrane phospholipid degradation, ultrastructural changes in the 
sarcolemmal membrane, and accumulation of pathological catabolic byproducts. 
Enhanced activation of calcium-dependent ATPases accelerates depletion of intra-
cellular ATP stores that have already been lowered following hypothermic arrest. 
This further perturbs cardiomyocyte sarcolemmal calcium transport channels 
that rely on ATP to maintain intracellular calcium homeostasis. Moreover, hypoxia 
during hyperkalemic cardioplegia increases mitochondrial calcium uptake via 
reversal of mitochondrial sodium/calcium exchangers in a manner akin to reversal 
of cardiomyocyte cell membrane sodium/calcium exchangers [41].
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Mitochondria can only endure so much calcium uptake before the onset of 
irreversible damage. Indeed, following reperfusion after hyperkalemic cardiople-
gia arrest, mitochondria exhibit increased oxygen free radical production and 
reduced superoxide dismutase activity, indicative of heightened oxidative stress 
[41]. Sustained oxidative stress can lead to opening of mitochondrial perme-
ability transition pores (MPTP), which promote mitochondrial swelling and 
mitochondrial membrane rupture. An assortment of mitochondrial enyzmes 
and molecules, such as cytochrome c, leak out into the cytosol through the 
MPTPs [41]. Cytochrome c is implicated in intrinsic apoptotic pathways through 
activation of cytosolic caspases and subsequent formation of myocardial apopto-
somes [41].
2.4.2 Myocardial apoptosis
Myocardial apoptosis during hyperkalemic cardioplegic ischemia–reperfusion 
merits further consideration for two major reasons. First, several studies have 
shown associations between hyperkalemic cardioplegic arrest and endothelial cell 
and cardiomyocyte apoptosis [42–44]. Second, several independent pathways of 
myocardial cell injury converge on apoptosis. Examples include mitochondrial 
oxidative stress and activation of an intrinsic apoptotic pathway (introduced 
earlier), or an extrinsic pathway driven by elevated humoral factors such as Fas or 
TNF-alpha acting on pro-apoptosis cell membrane receptors [44, 45]. Both intrinsic 
and extrinsic pathways converge upon a similar final common pathway that is 
chiefly regulated by two key protein groups: the Bcl-2 and cysteine protease caspase 
families [46, 47].
Within the Bcl-2 family, two proteins are particularly significant: Bcl-2 
itself, and Bad. The former is anti-apoptotic while the latter is pro-apoptotic. 
Phosphorylation inhibits Bad, blocking it from inactivating Bcl-2 [48]. Farther 
downstream in apoptotic signaling, cleavage of caspase 3 and poly ADP-ribose 
polymerase (PARP) is essential for ensuring final progression towards apoptosis. 
Meanwhile, apoptosis may also proceed via a caspase-independent pathway involv-
ing release of the mitochondrial flavoprotein apoptosis-inducing factor (AIF) from 
the mitochondria into the cytosol through MPTPs [49, 50].
A possible framework for understanding myocardial apoptosis after hyperka-
lemic CPB is as follows [48]. Activation of the intrinsic (mitochondrial) pathway 
leads to increased Bad activation/decreased Bcl-2 activation, which initiates the 
caspase cascade. Activation of the extrinsic pathway bypasses Bcl-2/Bad to directly 
activate the caspase cascade. As more and more caspases become activated, eventu-
ally terminal caspases, such as caspase 3, will be cleaved, leading to PARP cleavage. 
By this point, apoptosis has been irreversibly induced; DNA fragmentation and 
cell death quickly follow. In contrast, AIF translocation from the mitochondria to 
the cytosol may directly activate downstream/terminal caspases, bypassing initial/
intermediary constituents of the caspase cascade.
Studies have shown that caspase 3 cleavage and Bcl-2/Bad phosphorylation 
are significantly increased in myocardial tissue following hyperkalemic cold-
blood cardioplegia and reperfusion, even as total protein levels do not change 
[48]. Meanwhile, myocardial AIF levels increase slightly, accompanied by a trend 
towards nuclear translocation, consistent with a model of AIF induced chromatin 
condensation and DNA fragmentation as a mechanism of cell injury [48]. Note that 
both pro-apoptotic (e.g. caspase 3) and anti-apoptotic (e.g. phosphorylated Bad) 
mediators are activated—nevertheless, given the downstream terminal position of 
caspase 3, the overall balance in myocardial cells appears to be tipped in favor of 
pro-apoptotic signaling.
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Different formulations of hyperkalemic cardioplegia (e.g. cold crystalloid, warm 
blood, etc.) may exhibit differing degrees of myocardial protection and preven-
tion of apoptosis. Indeed, evidence exists suggesting that cold blood hyperkalemic 
cardioplegia is superior to warm blood, warm crystalloid, and cold crystalloid 
cardioplegia, in terms of increased Bad phosphorylation and decreased caspase 3 
activation [51]. Taken together, this combination of events appears to result in less 
apoptosis. In addition, these effects are associated with improved left ventricular 
function following cardioplegic arrest. However, this is not a universal finding in 
the literature. More work must be done to verify these conclusions and confirm if 
there truly is a definitive benefit to any one technique of hyperkalemic cardioplegia 
with respect to prevention of apoptosis.
2.4.3 Coronary vasomotor dysfunction
An extensive body of research has established that hyperkalemic solutions 
induce significant vasoconstriction when experimentally applied to coronary artery 
and aortic ring preparations [2]. Thus, it is no surprise that hyperkalemic cardiople-
gia induces significant functional changes to the microcirculation, especially the 
coronary circulation [52]. For example, a sizeable number of patients undergoing 
hyperkalemic cardioplegia experience coronary artery spasm [52].
Potassium can influence coronary vasoconstriction in several ways. Holding 
coronary vascular smooth muscle membrane potentials at sustained depolarization 
during hyperkalemic cardioplegia increases the likelihood of generating contrac-
tions [53]. Potassium may also act indirectly to cause vasospasm through action on 
the coronary endothelium. Indeed, endothelial vasoconstrictive and vasorelaxant 
factors govern homeostatic regulation of coronary vasomotor tone. These factors 
influence vascular smooth muscle through modulation of various cell membrane 
potassium channels, including calcium-activated potassium channels and ATP-
activated potassium channels [54, 55]. Important endothelial-derived relaxing 
factors include nitric oxide, endothelial-derived hyperpolarizing factor (EDHF), 
and cyclooxygenase enzymes. Important endothelial-derived constricting factors 
include endothelin-1 and thromboxane A2.
Porcine models of hyperkalemic cardioplegia showed that hyperkalemia signifi-
cantly attenuated EDHF-mediated relaxation in coronary artery preparations [56, 
57]. Moreover, hyperkalemic vasoconstriction has also been linked with impaired 
nitric oxide release [58] and impaired acetylcholine-dependent vascular relaxation 
[59, 60]. Potential mechanisms at play may involve potassium-induced inhibition 
of G protein and non-G protein signal transduction pathways, increased reactive 
oxygen and nitrogen species generation, decreased activity of endothelial nitric 
oxide synthase, and increased arachidonic acid metabolism [2]. Curiously, hyperka-
lemic cardioplegia has also been associated with decreased responsiveness of human 
coronary arterioles to the endothelial vasoconstrictors endothelin-1 and thrombox-
ane A2 [61, 62]. These findings testify to the complexity of mechanisms underpin-
ning coronary vasomotor dysfunction following hyperkalemic cardioplegia, most 
of which remain to be elaborated.
2.4.4 Myocardial and coronary endothelial dysfunction
Despite its cardioprotective effects, hyperkalemic cardioplegia-reperfusion can 
exert detrimental effects on the myocardial and coronary endothelium, promoting 
endothelial dysfunction [63, 64]. One aspect of endothelial dysfunction—pro-
duction of various endothelium-derived relaxing and contracting factors—was 
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discussed earlier due to its relevance in coronary vasospasm. Other important 
features of endothelial dysfunction during hyperkalemic cardioplegic arrest include 
endothelial injury, inflammation, reactive oxygen species production, coagulation 
cascade dysfunction, and endothelial tight junction degradation [52, 65–67]. All 
these adverse effects may occur with potassium levels as low as 10 mM, well within 
the realm of most hyperkalemic cardioplegic solutions [2]. To elaborate, potas-
sium concentrations of 30 mM in St. Thomas and Custodiol cardioplegic solutions 
proved considerably more damaging to the vascular endothelium than potassium 
concentrations of 20 mM, demonstrating the importance of strict potassium limits 
in hyperkalemic cardioplegic solutions [6].
A variety of structural changes to the vascular endothelium have been observed 
in experimental models of hyperkalemic cardioplegia. Key examples include 
endothelial intracellular vacuolization, membrane blebbing, adventitial fibrosis, 
and overall reduced viability [68, 69]. Furthermore, hyperkalemic cardioplegia 
promotes increased lipid uptake and cholesterol deposition in vascular intimae in 
primate models of post-graft venous atherosclerosis [70]. In addition, compromised 
endothelial adherens junctions during hyperkalemic cardioplegia mediate increased 
vascular permeability and tissue edema [67]. Indeed, animal models of cardiople-
gia/CPB show increased post-procedure VE cadherin, beta-catenin, and gamma-
catenin fragments, all of which are important structural components of adherens 
junctions [71]. In humans, increased endothelial cadherin phosphorylation, and 
decreased overall beta-catenin levels, have been observed in atrial tissue following 
hyperkalemic cardioplegia/CPB [72].
Details of specific mechanisms underlying these endothelial disturbances 
remain largely unclear; however, many possibilities exist. For example, it is gener-
ally agreed that depolarization induced by hyperkalemic cardioplegia is a critical 
initiating step of the underlying pathophysiology [2]. Endothelial depolarization 
increases activation of neutrophils, inflammation, voltage sensitive NAPDH 
oxidases, and platelets [62, 63, 73, 74]. Inflammation and neutrophil activation 
often reinforce each other, as pro-inflammatory cytokines like IL-1, IL-6, and TNF-
alpha further stimulate endothelial changes that promote neutrophil extravasation. 
NADPH oxidase catalyzes formation of important reactive oxygen species such as 
superoxide anions, which if left unchecked are severely cytotoxic. The amount of 
superoxide production during hyperkalemic cardioplegia has been linked to the 
extent of endothelial depolarization and translocation of the small G protein Rac 
from the cytosol to plasma membrane [75].
With respect to coagulation, potassium depolarization appears to have a direct 
stimulatory effect via enhancing ADP and collagen-induced platelet aggregation, 
along with an indirect effect through increased superoxide production [76, 77]. The 
latter appears to act through inhibition of endothelial NTPDases [78]. Membrane 
hyperpolarization reverses all these actions.
When left unchecked, sustained myocardial dysfunction following hyperka-
lemic cardioplegia-reperfusion may lead to myocardial stunning, a form of post-
operative left ventricular dysfunction [1]. Myocardial stunning often manifests as 
markedly reduced cardiac output without obvious evidence of infarction or injury 
(e.g. no signs of elevated troponin or CKMB in blood). Like myocardial apoptosis, 
myocardial stunning represents another final common pathway of convergence for 
several different pathophysiological mechanisms of hyperkalemic cardioplegia, 
chiefly dysregulated free radical production, coagulation imbalances, and exces-
sive catecholamine release [1]. However, unlike with apoptosis, in this scenario 
injury results from abnormal myocardial contractility as opposed to myocardial 
cell death.
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2.5 Postoperative potassium abnormalities: physiology and management
Postoperative imbalances in a variety of different electrolytes, including 
calcium, magnesium, potassium, and phosphate, have been observed following 
cardioplegia/CPB. Here, we will focus on potassium, beginning with hypokalemia. 
Hypokalemia can be defined as a serum potassium level that is less than 3.5 mEq/L 
[78]. Postoperative hypokalemia is a common finding after cardiac surgery involv-
ing hyperkalemic cardioplegia and CPB, and manifests almost immediately after 
the patient is weaned off the bypass circuitry [79]. Hence IV potassium supple-
mentation during cardioplegia is extremely important to mitigate against the most 
severe manifestations [80].
However, even with electrolyte supplementation in the operating room, CPB 
poses a high risk of post-procedure electrolyte depletion [81]. The pivotal role of 
potassium in normal cardiac contractility means that disturbances in potassium 
homeostasis significantly increase the risk of arrythmias and, in severe cases, 
sudden cardiac arrest. Indeed, arrythmias, especially atrial tachyarrhythmias (e.g. 
atrial fibrillation, atrial flutter) and, less frequently, ventricular arrhythmias, are a 
major source of morbidity and mortality following cardiac surgery [82, 83].
Specific mechanisms underpinning this phenomenon remain largely unclear; 
however, a variety of possibilities exist [78]. For example, poor oral intake of 
potassium-rich foods prior to cardiac surgery may contribute to enhanced depletion 
during surgery. In addition, prolonged preoperative use of digoxin, along with thia-
zide and loop diuretics may play a role. These agents may cause hypomagnesemia 
(low magnesium levels), which can contribute to extracellular potassium depletion. 
Under normal circumstances, intracellular magnesium binds to and blocks the 
pores of renal outer medullary potassium (ROMK) channels in the distal nephron, 
preventing outward flux of potassium into the renal tubular network [78]. Thus 
hypomagnesemia may remove this physiologic limiter, leading to increased renal 
clearance of potassium.
A hyperactive aldosterone response to stress may also be implicated, particularly 
in the context of congestive heart failure [78, 80]. Moreover, increased catechol-
amine (norepinephrine and epinephrine) release during cardiopulmonary bypass 
may facilitate hypokalemia given the influence of catecholamines on plasma potas-
sium [84, 85]. Animal models have shown that elevated catecholamine levels can 
produce first, a transient hyperkalemia due to activation of hepatic calcium-depen-
dent potassium channels by alpha adrenergic stimulation and second, a sustained 
hypokalemia by stimulation of skeletal muscle Na-K ATPase [86]. Such studies need 
to be replicated in humans undergoing cardiopulmonary bypass-hyperkalemic 
cardioplegia in order to verify the applicability of these putative mechanisms.
Because glucose is often given during cardioplegia, insulin may also be admin-
istered to minimize the chances of hyperglycemia. However, given that insulin acts 
as a regulator of potassium distribution between intracellular and extracellular 
fluid compartments by stimulating Na-K ATPase activity, it is possible that insulin 
administration during and after cardioplegia may contribute to potassium deple-
tion [87]. Next, given that many cardioplegic solutions in current practice are cold 
hyperkalemic solutions, any potential impact of hypothermia on potassium homeo-
stasis during cardiac surgery cannot be ignored. As with insulin, hypothermia has 
been linked to an intracellular shift of potassium away from the extracellular space 
through as-yet unelaborated mechanisms [88]. Finally, the CPB circuit itself has 
been shown to significantly dilute overall blood plasma protein concentrations, 
which may also affect plasma ion homeostasis [89].
In general, treatment of postoperative hypokalemia largely centers on admin-
istration of potassium chloride (KCl) solution to elevate extracellular potassium 
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concentrations to physiologic levels. Indeed, in the case of pediatric cardiac ICU 
patients for whom enteral potassium supplementation is contraindicated, IV KCl 
administration is one of the only available tools for correcting hypokalemia [90]. 
For most patients, this proves sufficient to correct the imbalance and stave off the 
development of hypokalemia-induced arrhythmias. However, in a small minority, 
external KCl solution does not reverse the hypokalemia—and so in these patients, 
the chances of arrhythmias increase exponentially.
Although hypokalemia is the most common potassium electrolyte abnormality 
following hyperkalemic cardioplegia-CPB, postoperative hyperkalemia may occur 
under certain, albeit rarer, circumstances. In general, postoperative hyperkalemia 
is a concern mainly in patients with renal failure undergoing CPB, most likely due 
to renal tubular dysfunction [91]. Severe hyperkalemia may be treated with IV 
calcium gluconate, an insulin-dextrose regimen, and diuretics [92]. If a patient has 
end-stage renal disease, dialysis may be the best option to treat hyperkalemia, along 
with IV calcium to stabilize the myocardium and IV insulin to shift potassium into 
cells [93].
2.6 Alternatives to hyperkalemic cardioplegia
Hyperkalemic cardioplegia is by far the most widely used method of cardiople-
gia in current clinical practice. However, because of the numerous perioperative 
repercussions of hyperkalemic cardioplegia, a variety of attempts have been made 
to explore alternative approaches. Given that many adverse effects of hyperkalemic 
cardioplegia stem from its induction of depolarized arrest, one popular avenue of 
investigation has been the possibility of hyperpolarized arrest. Hyperpolarization 
is the natural resting state of cardiomyocytes, so in theory, arresting the heart at its 
baseline hyperpolarized state may better preserve physiological integrity. In isolated 
animal heart models, hyperpolarized arrest has been achieved via pharmacologic 
activation of ATP-sensitive potassium channels [94, 95]. Following reperfusion, this 
form of hyperpolarized arrest appeared to lead to improved postischemic func-
tional recovery when compared to hearts protected with depolarized arrest.
Meanwhile, so-called “polarized arrest” has been proposed as another alter-
native to hyperkalemic cardioplegia. The core principle behind this concept is 
administration of sodium channel blockers, such as procaine in humans or tetro-
dotoxin in animal models [96]. Sodium channel blockade prevents depolarization-
induced activation of calcium currents, which normally carry out the bulk of the 
cardiomyocyte action potential. Overall, in animal models, tetrodotoxin-induced 
polarized arrest reduces metabolic demands during ischemia, including myocardial 
oxygen consumption, more so than hyperkalemic cardioplegia [96]. Furthermore, 
polarized arrest may produce less significant postoperative ionic imbalances, with 
further protection provided by coincident administration of sodium/potassium/
chloride transporter and sodium/proton exchanger inhibitors [96]. Nonetheless, 
more work needs to be done to verify the broader clinical applicability of these 
alternatives to hyperkalemic cardioplegia.
3. Conclusions
By taking advantage of the pivotal role of potassium in cardiomyocyte 
physiology, hyperkalemic cardioplegia has become an integral tool for cardiac 
surgery. From the early days of Dennis Melrose’s simple potassium citrate solu-
tion to complex modern-day formulations such as the Del Nido and Buckberg 
media, approaches to developing and administering hyperkalemic cardioplegic 
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solutions have evolved considerably, with a continuing focus on developing 
the most cardioprotective and least damaging solutions possible. While initial 
approaches to hyperkalemic cardioplegia revolved around hypothermic solutions, 
normothermic/“warm” solutions, along with blood as opposed to crystalloid-based 
solutions, are gaining momentum as potential alternatives to mitigate adverse 
perioperative consequences of cold hyperkalemic cardioplegia. Some of those 
consequences include myocardial calcium loading, myocardial apoptosis, coronary 
vasomotor dysfunction, myocardial endothelial dysfunction, and myocardial stun-
ning. With any form of hyperkalemic cardioplegia, plasma potassium abnormalities 
following reperfusion, mainly postoperative hypokalemia, remain a persistent 
clinical concern. And while most patients respond well to IV KCl supplementation, 
some do not and proceed to develop fatal arrythmias, underscoring the need for 
further research to understand the mechanisms at play and develop new treat-
ments. In the future, it is possible that other approaches such as hyperpolarized or 
polarized arrest may challenge the widespread use of depolarized hyperkalemic 
cardioplegic arrest. Nevertheless, for the time being, hyperkalemic cardioplegia 
remains dominant in cardiac surgery, and will likely continue to be so for some time 
to come.
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